nivolumab,ipilimumab,cabozantinib
bms,exelixis
['triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)']
amazing discussion by about the triplet data in mrcc. many questions stay after the cosmic results and it is not time to move forward for the triplet in the clinical practice. #esmo2022 
Scientific Committee Member LACOG - GU. Medical Oncologist at Hospital Albert Einstein and CPO. Owner and founder BIO. Following or RT does not mean endorsement